Abstract

Biotechnology Law ReportVol. 34, No. 5 The Holman ReportThe Biotechnology Industry Organization (BIO) and Pharmaceutical Research and Manufacturers of America (PhRMA) Seek En Banc Review of Ariosa Diagnostics v. SequenomChristopher M. HolmanChristopher M. HolmanSearch for more papers by this authorPublished Online:21 Oct 2015https://doi.org/10.1089/blr.2015.29011.holAboutSectionsView articleView Full TextPDF/EPUB ToolsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail View article"The Biotechnology Industry Organization (BIO) and Pharmaceutical Research and Manufacturers of America (PhRMA) Seek En Banc Review of Ariosa Diagnostics v. Sequenom." Biotechnology Law Report, 34(5), pp. 169–170FiguresReferencesRelatedDetailsCited byCongress Considering Legislation Intended to Reverse the Recent Trend Toward Devaluation of the U.S. Patent Right Christopher M. Holman9 October 2018 | Biotechnology Law Report, Vol. 37, No. 5Current 35 U.S.C. § 101 Limits of Patentability in the Life Sciences and Their Impact on Sequenom Kathryn A. Piffat15 April 2016 | Biotechnology Law Report, Vol. 35, No. 2 Volume 34Issue 5Oct 2015 InformationCopyright 2015, Mary Ann Liebert, Inc.To cite this article:Christopher M. Holman.The Biotechnology Industry Organization (BIO) and Pharmaceutical Research and Manufacturers of America (PhRMA) Seek En Banc Review of Ariosa Diagnostics v. Sequenom.Biotechnology Law Report.Oct 2015.169-170.http://doi.org/10.1089/blr.2015.29011.holPublished in Volume: 34 Issue 5: October 21, 2015PDF download

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.